Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration

Bristol-Myers Squibb Company (NYSE: BMY) and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news